within Pharmacolibrary.Drugs.ATC.J;

model J02AX01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.025,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0115,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Flucytosine is an antifungal medication used primarily in combination with other agents (commonly amphotericin B) for the treatment of severe systemic fungal infections such as cryptococcal meningitis and candidiasis. It acts as a pyrimidine analog, interfering with fungal DNA and RNA synthesis. Flucytosine is approved by regulatory agencies and remains in use today, mainly for specific difficult-to-treat infections and susceptible organisms.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data for orally administered flucytosine in adult patients with normal renal function.</p><h4>References</h4><ol><li><p>Fisher, JF, et al., &amp; Newman, CA (2011). Candida urinary tract infections--treatment. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 52 Suppl 6 S457–S466. DOI:<a href=&quot;https://doi.org/10.1093/cid/cir112&quot;>10.1093/cid/cir112</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21498839/&quot;>https://pubmed.ncbi.nlm.nih.gov/21498839</a></p></li><li><p>Béguin, J, et al., &amp; Maurey, C (2021). Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs. <i>BMC veterinary research</i> 17(1) 220–None. DOI:<a href=&quot;https://doi.org/10.1186/s12917-021-02927-5&quot;>10.1186/s12917-021-02927-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34154593/&quot;>https://pubmed.ncbi.nlm.nih.gov/34154593</a></p></li><li><p>Pai, MP, et al., &amp; Felton, LA (2010). Clinical pharmacokinetics of oral controlled-release 5-fluorocytosine. <i>Antimicrobial agents and chemotherapy</i> 54(3) 1237–1241. DOI:<a href=&quot;https://doi.org/10.1128/AAC.01103-09&quot;>10.1128/AAC.01103-09</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20038612/&quot;>https://pubmed.ncbi.nlm.nih.gov/20038612</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J02AX01;
